Kuros Biosciences Ltd.

Earnings Release • Jul 22, 2010

News Details

Corporate | 22 July 2010 07:00

Cytos Biotechnology Second Quarter Report 2010

Cytos Biotechnology AG / Half Year Results

22.07.2010 07:00

Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Cytos Biotechnology Ltd Second Quarter Report 2010 as of June 30, 2010

Summary of important events in Q2 2010

• Placebo-controlled phase II study shows CYT003-QbG10 is safe and
  efficacious for the treatment of allergic asthma

• Cytos Biotechnology sells platform technology for the identification of
  monoclonal antibodies to Intercell for EUR 15 million

• Constitution of the Board of Directors after the Shareholder's Meeting
  2010

• Harry Welten succeeds Jakob Schlapbach as CFO, Jakob Schlapbach elected
  to the Board of Directors

• Upcoming events:

• Presentation at the European Respiratory Society 2010 Annual Congress,
  September 18-22, 2010 in Barcelona, Spain

• Presentation at the Swiss Equity conference zurich, September 14/15,
  2010 in Zurich, Switzerland

• Presentation at the Modern Vaccines/Adjuvants Formulation 2010
  Conference, October 13-15, 2010 in Cannes, France

• Presentation at the Next Generation Vaccines Conference, October 21/22,
  2010 in Vienna, Austria

• Financial summary

in CHF million YTD* 10 YTD* 09 Q2 10 Q2 09
Revenue 21.4 6.6 21.2 6.3
Net operating costs (14.4) (22.4) (7.5) (11.4)
Net income/(loss) 11.2 (18.0) 15.0 (6.2)

                                  06/30/10  12/31/09

Cash, cash equivalents, 56.6 60.5
financial assets
and trade receivables
Nominal value of the convertible 41.1 57.1
bonds not held by
Cytos Biotechnology Ltd
Full-time employees (number) 76 85
* YTD = year to date January 1 - June
30

The complete Second Quarter Report 2010 can be downloaded on Cytos
Biotechnology's website under the following link:

http://www.cytos.com/userfiles/file/Cytos_Q2_2010_E.pdf

Harry Welten, MBA
Chief Financial Officer
Cytos Biotechnology Ltd
Phone: +41 44 733 46 46
Fax: +41 44 733 47 02
e-Mail: harry.welten@cytos.com
Website: www.cytos.com

22.07.2010 Ad hoc announcement, Financial News and Press Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Schweiz
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info@cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number: -
Listed: Freiverkehr in Berlin, München, Stuttgart; Open
Market in Frankfurt; Foreign Exchange(s) SIX

End of News DGAP News-Service

---